share_log
Moomoo 24/7 ·  Apr 22 08:03
Corcept Therapeutics Says Patients In The Open-Label Phase Exhibited Clinically Meaningful And Statistically Significant Improvements In Hypertension, Hyperglycemia And Other Key Secondary And Exploratory Endpoints
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment